MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Axsome Therapeutics Inc

Closed

SectorHealthcare

118.79 0.17

Overview

Share price change

24h

Current

Min

116.99

Max

119.98

Key metrics

By Trading Economics

Income

11M

-48M

Sales

29M

150M

Profit margin

-31.973

Employees

846

EBITDA

20M

-37M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+44.25% upside

Dividends

By Dow Jones

Next Earnings

3 Nov 2025

Market Stats

By TradingEconomics

Market Cap

678M

6B

Previous open

118.62

Previous close

118.79

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Axsome Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 Oct 2025, 20:45 UTC

Earnings

Costco Wholesale Sales Climb in September, Early October

8 Oct 2025, 20:12 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 Oct 2025, 16:39 UTC

Major Market Movers

Mining Shares Rise as Gold Prices Soar

8 Oct 2025, 23:45 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8 Oct 2025, 23:43 UTC

Market Talk

Gold Falls on Possible Profit-Taking -- Market Talk

8 Oct 2025, 23:18 UTC

Acquisitions, Mergers, Takeovers

JD Logistics to Finance Acquisition Using Internal Funds

8 Oct 2025, 23:17 UTC

Acquisitions, Mergers, Takeovers

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 Oct 2025, 23:16 UTC

Acquisitions, Mergers, Takeovers

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 Oct 2025, 21:54 UTC

Market Talk
Earnings

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 Oct 2025, 21:30 UTC

Market Talk

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 Oct 2025, 21:26 UTC

Market Talk
Earnings

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 Oct 2025, 19:15 UTC

Market Talk

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 Oct 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 Oct 2025, 18:47 UTC

Market Talk

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 Oct 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 Oct 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

TaskUs Will Remain a Publicly Traded Co >TASK

8 Oct 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 Oct 2025, 18:45 UTC

Acquisitions, Mergers, Takeovers

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 Oct 2025, 18:07 UTC

Market Talk

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 Oct 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

8 Oct 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 Oct 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 Oct 2025, 15:57 UTC

Market Talk

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 Oct 2025, 15:56 UTC

Market Talk

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 Oct 2025, 15:53 UTC

Market Talk

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 Oct 2025, 15:44 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 Oct 2025, 15:44 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 Oct 2025, 15:43 UTC

Acquisitions, Mergers, Takeovers

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 Oct 2025, 15:42 UTC

Acquisitions, Mergers, Takeovers

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Peer Comparison

Price change

Axsome Therapeutics Inc Forecast

Price Target

By TipRanks

44.25% upside

12 Months Forecast

Average 171.14 USD  44.25%

High 200 USD

Low 144 USD

Based on 16 Wall Street analysts offering 12 month price targets forAxsome Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

16

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

107.24 / 112.29Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Strong Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat